Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging.
Alzheimer Dis Assoc Disord
; 32(1): 35-42, 2018.
Article
in En
| MEDLINE
| ID: mdl-29140859
ABSTRACT
INTRODUCTION:
Few studies to date have explored patient and caregiver views on the clinical use of amyloid positron emission tomography (PET).METHODS:
A 7-item questionnaire assessing patient and caregiver views (510 total respondents) toward amyloid PET imaging was advertised broadly through alz.org/trialmatch.RESULTS:
We received 510 unique responses from 48 US states, 2 Canadian provinces, the Dominican Republic, and Greece. Both patients and caregivers indicated that they would want to receive amyloid imaging if offered the opportunity. Over 88% of respondents had a positive response (â¼10% with neutral and 2% with negative responses) to whether amyloid PET should be offered routinely and be reimbursed. Such information was felt to be useful for long-term legal, financial, and health care planning. Respondents identifying with early age cognitive decline (younger than 65 y) were more likely to explore options for disability insurance (P=0.03). Responders from the Midwest were more likely to utilize information from amyloid imaging for legal planning (P=0.02), disability insurance (P=0.02), and life insurance (P=0.04) than other US regions.DISCUSSION:
Patients and caregivers supported the use of amyloid PET imaging in clinical practice and felt that the information would provide significant benefits particularly in terms of future planning.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Amyloid beta-Peptides
/
Caregivers
/
Early Diagnosis
/
Positron-Emission Tomography
/
Alzheimer Disease
Type of study:
Diagnostic_studies
/
Prognostic_studies
/
Qualitative_research
/
Screening_studies
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Alzheimer Dis Assoc Disord
Journal subject:
NEUROLOGIA
/
PSIQUIATRIA
Year:
2018
Document type:
Article